UniQure, Syndax, Erasca Drawing Fresh Analyst Interest
Three clinical-stage biotechs—UniQure, Syndax, and Erasca—are catching analyst attention ahead of key catalysts, with...
Using index funds for stock diversification can simplify your investment strategy. Explore how they can provide broad market exposure.
23,126 articlesThree clinical-stage biotechs—UniQure, Syndax, and Erasca—are catching analyst attention ahead of key catalysts, with...
A fresh look at HAIN's Q3 2026 earnings and what it means for investors. Learn the metrics that matter, how to read t...
Investors are rethinking where to place bets as AI hype cools. Transportation stocks offer diversification and exposu...
A SpaceX rumor about a full tech stack tied to Apple investor impact sparked a volatile session for AAPL, even as Elo...
Artificial intelligence is reshaping medicine, from drug discovery to patient care. This article spotlights two healt...
The AI chip rally is shifting from training to real-world inference. This article explains why the next phase chip su...
Dell Technologies stunned markets with a Q1 FY27 results beat, led by AI-optimized servers and a rising backlog. The ...
Palantir rallies on stronger AI demand and improving margins, positioning it as a core pick in this best stocks 2026 ...
What to expect from Kodiak’s 2025 earnings? This guide breaks down revenue drivers, margins, and realistic scenarios ...
Praxis (Prax) 2026 earnings signals a path from solid growth to stronger profitability. This analysis breaks down the...
Two North American midstream giants posted earnings that point to divergent paths for dividend investors in 2026. ENB...
As investors eye helen troy (hele) 2027, the Q1 earnings call could reveal how branded consumer products, e-commerce ...